NDAOPHTHALMICOINTMENT1 Generic Approved
Approved
Jul 1963
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Data completeness
5/8 — Partial
MAXITROL (neomycin sulfate, polymyxin b sulfate and dexamethasone) by Novartis is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1963.
Drug data last refreshed 4h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXITROL is a fixed-dose combination ophthalmic ointment containing neomycin sulfate, polymyxin B sulfate, and dexamethasone approved in 1963. It combines broad-spectrum antibiotics with a potent corticosteroid to treat bacterial eye infections with inflammatory components. The corticosteroid works via hormone receptor agonism to suppress inflammation while antibiotics address bacterial pathogens.
$0.003BPart D
LOE ApproachingMinimal commercial activity ($3K Part D spending, 28 claims in 2023) signals a mature, declining product with limited team expansion opportunity and focus on market defense.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for MAXITROL roles, reflecting its LOE approaching status and low commercial priority ($3K Part D spending). Career opportunities on this product are limited to retention and management roles rather than expansion, growth, or launch activities.
Brand ManagerProduct Manager
Worked on MAXITROL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.